论文部分内容阅读
目的:观察盐酸贝尼地平治疗原发性轻中度高血压患者的疗效、安全性。方法:采取随机双盲对照观察法。原发性轻中度高血压的患者经安慰剂治疗两周,血压符合入选标准者,随机分为二组。分别给予盐酸贝尼地平4mg每日1次或氨氯地平5mg每日1次,第2周末,如舒张压≥90mmHg则剂量加倍,继续治疗6周。观察贝尼地平降压疗效及安全性。结果:两组血压治疗后均显著下降,治疗前后均有显著差异(P<0.001),但二组之间无显著差异(P>0.05)不良反应在两组间无统计学差异。心率的改变两组治疗前后无统计学差异(P>0.05)。结论:贝尼地平能有效降低轻中度原发性高血压患者的血压,疗效与氨氯地平组无统计学差异。具有较好安全性和耐受性。
Objective: To observe the efficacy and safety of benidipine hydrochloride in patients with primary mild to moderate hypertension. Methods: Randomized double-blind control observation. Patients with primary mild-to-moderate hypertension were treated with placebo for two weeks, and blood pressure met the inclusion criteria and were randomly assigned to two groups. They were given benidipine hydrochloride 4mg once daily or amlodipine 5mg once daily, and the second weekend, if the diastolic blood pressure was greater than or equal to 90mmHg, the dosage was doubled and the treatment was continued for 6 weeks. To observe the antihypertensive efficacy and safety of benidipine. Results: The blood pressure of both groups decreased significantly after treatment, with significant difference before and after treatment (P <0.001), but there was no significant difference between the two groups (P> 0.05). There was no significant difference in adverse reactions between the two groups. Heart rate changes in two groups before and after treatment was no significant difference (P> 0.05). Conclusion: Benidipine can effectively reduce the blood pressure in patients with mild to moderate essential hypertension, with no significant difference between the efficacy and the amlodipine group. Has good security and tolerance.